Paul Goode, GlucoTrack’s CEO, wants to “keep pushing the boundaries” by giving people living with diabetes an alternative to standard glucose monitoring technology. While still early in development, the company’s innovative long-term implantable continuous glucose monitor (CGM) technology has shown promising results.
A new set of early study results, published in January, that studied a small sample size of sensors, suggested that its sensors are safe and capable of a high level of accuracy. This follows preliminary results from a
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?